Collegium Pharmaceutical Inc represents a set of values and a corporate philosophy that guide its operations. The company is committed to improving patients' lives by developing and delivering innovative and abuse-deterrent therapies. Collegium places great importance on innovation, patient focus, and responsibility to shareholders. With a strong dedication to research and development, Collegium aims to address unmet medical needs and enhance patient outcomes. By continuously striving for excellence, Collegium Pharmaceutical Inc aims to maintain its position as a leading provider of pharmaceutical solutions.

Collegium Pharmaceutical Inc is primarily present in the United States.

Collegium Pharmaceutical Inc has achieved several significant milestones. One notable achievement of the company was the FDA approval of its product Xtampza ER, an abuse-deterrent opioid medication for the management of severe pain. This approval showcases Collegium Pharmaceutical's dedication to developing innovative treatment options. Additionally, the company successfully launched Xtampza ER and established partnerships with reputable pharmaceutical companies for commercialization. Collegium Pharmaceutical Inc has also demonstrated continuous growth and expansion, reflecting its commitment to providing effective and safe medications to patients. Through its notable achievements, Collegium Pharmaceutical Inc has solidified its position as a leading player in the pharmaceutical industry.

Collegium Pharmaceutical Inc is a pharmaceutical company specializing in the development and commercialization of innovative prescription products for pain management. Founded in 2002, Collegium Pharmaceuticals has a strong history of delivering effective treatments for pain while striving to address the challenges associated with opioid misuse and abuse. The company focuses on utilizing its proprietary DETERx platform to develop abuse-deterrent medications for the treatment of various pain conditions. Collegium Pharmaceutical Inc aims to provide healthcare professionals and patients with safe and effective options for pain management, contributing to improved patient outcomes and reducing the risk of opioid abuse.

The main competitors of Collegium Pharmaceutical Inc in the market are pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., and AstraZeneca.

Collegium Pharmaceutical Inc is primarily active in the pharmaceutical industry.

Collegium Pharmaceutical Inc operates under a business model focused on developing and commercializing innovative medicines. As a specialty pharmaceutical company, Collegium specializes in developing products for the treatment of pain and related conditions. The company's primary goal is to provide patients with effective, safe, and abuse-deterrent pain management solutions. Collegium Pharmaceutical Inc strives to continually advance its portfolio by leveraging its proprietary technology platform, known as DETERx®, to enhance the delivery of active ingredients. This innovative business model allows Collegium to bring valuable medications to market while prioritizing patient safety and therapeutic effectiveness.

P/E odnos Collegium Pharmaceutical iznosi 8,03.

KUV kompanije Collegium Pharmaceutical iznosi 2,63.

AlleAktien kvalitativni skor za Collegium Pharmaceutical je 6/10.

očekivana Collegium Pharmaceutical promet je 631,87 mil. USD.

Dobit očekivana Collegium Pharmaceutical je 206,60 mil. USD.

Collegium Pharmaceutical Inc is an innovative company specialized in the development and marketing of medications for patients with pain and inflammation conditions. The company's business model is based on innovation and providing a differentiated product range to meet the needs of their target audience. The company offers a wide range of products, including opioid analgesics and narcotic antagonists. Collegium offers various branded medications such as Xtampza® ER, Nucynta® ER, and DETERx®, all of which have different effects on the body and are suitable for different pain conditions. The company's main focus is on research and development of new medications. Collegium dedicates significant financial resources to the research and development of pain treatment drugs. They have a variety of patented drugs in the development phase and are continuously striving to improve therapy options for pain patients. Additionally, Collegium invests in expanding its business model into new markets. The company has expanded its presence in international markets to reach a larger customer base and expand their business. Through partnerships with local companies, Collegium has increased its reach and global presence. Collegium also constantly strives to improve the efficiency and effectiveness of its business processes. The company invests in technology and automation to improve operational efficiency and enhance product quality. This also helps to identify cost savings in areas such as sales, procurement, and inventory management. Another important aspect of Collegium's business model is its partnership with service providers and distributors. The company works closely with pharmacies, medical facilities, and other healthcare organizations to sell its products and services. These partnerships bring additional sales and increase Collegium's visibility and credibility in the industry. Overall, Collegium offers a broad and esteemed portfolio of pain medications. The company follows an innovative business model based on strong innovation, partnerships, expansion into new markets, and a focus on efficient business processes. Collegium will continue to actively strive to maintain its position as a leading company in pain treatment and expand its business on a continuous basis.

Collegium Pharmaceutical isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Collegium Pharmaceutical trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Collegium Pharmaceutical je US19459J1043.

WKN od Collegium Pharmaceutical je A14SUV.

Oznaka za praćenje akcija kompanije Collegium Pharmaceutical je COLL.

U poslednjih 12 meseci, Collegium Pharmaceutical je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Collegium Pharmaceutical će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Collegium Pharmaceutical trenutno iznosi .

Collegium Pharmaceutical isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Collegium Pharmaceutical je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Collegium Pharmaceutical se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Collegium Pharmaceutical od 2. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 2. 10. 2024..

Isplata poslednje dividende izvršena je 2. 10. 2024..

U godini 2023 kompanija Collegium Pharmaceutical je isplatila 0 USD kao dividende.

Dividende od Collegium Pharmaceutical se isplaćuju u USD.